Business Context and Reporting Period
Company: Synthetic Blood International, Inc. (Note: Metadata referenced Tenax Therapeutics, but filing text identifies Synthetic Blood International, Inc.)
Reporting Period: Quarterly period ended October 31, 1996 (Six months ended Oct 31, 1996 vs. Oct 31, 1995).
Status: Development Stage Company in pre-clinical trial stage. No principal operations commenced.
Going Concern: Substantial doubt exists regarding the ability to continue as a going concern due to accumulated losses of $7.39 million and the need for significant additional financing for FDA testing.
Key Financial Metrics
| Metric | Six Months Ended Oct 31, 1996 | Six Months Ended Oct 31, 1995 |
|---|---|---|
| Revenue | $0 (No revenue reported) | $0 |
| Net Loss | $(1,013,053) | $(1,430,649) |
| Accumulated Deficit | $(7,389,809) | $(6,376,756) |
| Cash and Equivalents (End of Period) | $138,760 | $138,760 |
| Working Capital | $(29,342) Deficit | Not explicitly stated |
| Total Current Assets | $347,886 | $106,124 |
| Total Current Liabilities | $377,228 | $974,969 |
| Net Cash Used in Operating Activities | $(6,583,445) | $(1,336,886) |
| Net Cash Provided by Financing Activities | $7,242,796 | $1,402,269 |
Material Changes vs. Prior Period
- Expense Reduction: Net loss decreased by approximately 43% compared to the prior six-month period, driven by a significant reduction in research personnel and outside laboratory testing costs.
- Research & Development: R&D expenses for the six months ended Oct 31, 1996, were reported as $284,047 in the MD&A section (contrasting with $625,289 in the Statement of Operations table for the same period). The filing attributes the decrease to reduced staffing and testing.
- Liquidity Improvement: Total current assets increased from $106,124 to $347,886, primarily due to cash inflows from financing activities, though a working capital deficit of $29,342 remains.
- Liability Restructuring: Total current liabilities decreased significantly from $974,969 to $377,228, largely due to the conversion of stockholder loans and accrued payroll into common stock.
Guidance, Outlook, and Risks
- Outlook: The company is pre-clinical and requires significant additional financing to proceed with Phase I, II, and III human testing and FDA approval. No assurance is given that funding will be obtained or FDA approval granted.
- Financing Strategy: Management is actively pursuing strategic alliances, joint ventures, and private placements. Recent financing included proceeds from the sale of common stock ($5.18M) and convertible debentures ($780k).
- Risks:
- Going Concern: Continuation depends on generating cash flow and obtaining external financing.
- Regulatory: Products must undergo further testing prior to FDA submission; approval is not guaranteed.
- Commitments: Future employment commitments of $411,000 in 1997 and $272,000 in 1998.
- Licensing: Royalty obligations of at least $30,000 annually for the next three years, increasing to $200,000 thereafter.
Investor Verification Checklist
- Discrepancy in R&D Expenses: Verify the correct R&D expense figure for the six months ended Oct 31, 1996, as the MD&A states $284,047 while the Statement of Operations table lists $2,682,349.
- Cash Burn Rate: Confirm the sustainability of operations given the net cash used in operating activities of $6.58 million versus cash on hand of $138,760.
- Stock Dilution: Review the impact of recent equity issuances (over 7 million shares issued in the period) on existing shareholder value.
- Debt Conversion: Verify the terms and valuation of stock issued to cancel $581,763 in loans and accrued payroll.
- Going Concern Status: Assess the timeline and probability of securing the "significant additional financing" required to reach clinical trials.